Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Questioning imiquimod's impact on scars
National report - Best known as the modern-day defender against basal cell carcinoma and actinic keratoses, imiquimod 5 percent cream (Aldara) is also gaining a reputation for its biosynthetic and clinical results in the treatment of scars - and evidence continues to mount supporting the immune response modifier's prominence in repealing one of the most notorious of scars: keloids.
Related Videos
Related Content
